Best-in-Class through Innovation
Our goal is to create the ADHD treatment of choice for clinicians and patients. CTx has committed to achieving best-in-class status by employing the most advanced, innovative technologies and therapies available to treat the disorder.
Patient-Centric Philosophy to Overcome Long-standing Unmet Need
In 1798, Scottish physician Sir Alexander Crichton first published specific examples of an ADHD-like disorder. Since that time, patients and physicians alike have sought an ADHD treatment that works quickly, provides appropriate duration and is safe and well tolerated. We aim to overcome this long-standing unmet need by providing new and exceptional treatment options for clinicians and patients.
Fast-Track to Proof of Concept
The company's lead product, CTX-1301, is expected to complete initial Phase I/Phase II human trials in early 2015. Furthermore, by utilizing a streamlined regulatory approach, CTx speeds development, greatly reduces development costs and improves time to market.
Capital Efficiency – Investor Value
CTx has carefully structured a financing strategy that maximizes developmental output and minimizes owner & investor dilution that typically occurs during early stage development; thereby increasing overall return on investment for all parties. Furthermore, capital on hand is allocated towards clinical development activities and acquisition of expert consultants to further enhance value.
Intellectual property rights and patents are the lifeblood of innovation and development in the biotechnology sector. Consequently, CTx focuses considerable resources into the licensing and construction of formidable patent estates.
Passion to improve the quality of life for those with ADHD and other serious neurobiological disorders runs deep amongst the founders of Cingulate Therapeutics. It is a passion borne out of careers focused on innovation, research and a commitment to patient care—and for several of our founders—borne out of the daily care for members of our own families affected by these disorders.